MeSH D006947 - hyperkalemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| AstraZeneca | Sodium zirconium cyclosilicate | Lokelma | 2032-02-10 | 2018-05-18 | $233 M | Q2/21-Q2/24 |
| Vifor | Patiromer | Veltassa |  | 2017-07-19 |  |  |
| Mylan | Polyethylene glycol 3350, Tezacitabine, Sodium chloride, Sodium bicarbonate | Colyte With Flavor Packs |  | 1984-10-26 |  |  |
| Rising Pharmaceuticals | Polyethylene glycol 3350, Tezacitabine, Sodium chloride, Sodium bicarbonate | Peg 3350 Electrolytes |  | 2010-01-28 |  |  |
| Polyethylene glycol 3350, Sodium chloride, Sodium bicarbonate | Peg, Potassium Chloride, Bicarbonate, |  | 2010-04-02 |  |  | |
| Belcher Pharmatech | Sodium polystyrene sulfonate | Polystyrene Sulfonate |  | 2016-02-23 |  |  |
| Nostrum Laboratories | Polyethylene glycol 3350, Sodium chloride, Sodium bicarbonate | Peg, Potassium Chloride, Bicarbonate, |  | 2017-03-08 |  |  |
| Baxter | Sodium chloride, Sodium bicarbonate | Phoxillum B22k |  | 2015-01-13 |  |  |
| Dextrose, Lactic acid, Sodium chloride, Sodium bicarbonate | Prismasol |  | 2006-10-25 |  |  |
Clinical Trials
Historical Success Rate
Phase 1
25%1/4
Phase 2
78%7/9
Phase 3
58%7/12
Approved: 5Overall Success rate: 11%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use